In-vitro treatment of probiotics in PBMCs shows increased CD8+ T cell/Treg cell ratios, higher IFN-γ production by NK, CD4+ T, and γδ T cells, improved tumor recognition, and enhanced cytotoxicity and tumor growth inhibition via differentiation. The gene discussed is CD8A; the disease is neoplasm.